Riluzole Oral Soluble film (ROSF) 50 mg
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Apr 4, 2018 → Dec 21, 2018
NCT ID
NCT03679975About Riluzole Oral Soluble film (ROSF) 50 mg
Riluzole Oral Soluble film (ROSF) 50 mg is a phase 2 stage product being developed by Aquestive Therapeutics for Amyotrophic Lateral Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03679975. Target conditions include Amyotrophic Lateral Sclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03679975 | Phase 2 | Terminated |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 44 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 52 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 23 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 65 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 65 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 77 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 52 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 33 |
| TCH346 | Novartis | Phase 2 | 52 |
| VHB937 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| BLZ945 | Novartis | Phase 2 | 52 |
| TRO19622 | Roche | Phase 2/3 | 65 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 77 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 40 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 51 |